REGENXBIO grants RSUs to CMO and CSO to promote stability during CEO transition

REGENXBIO Inc.

On August 1, 2024, REGENXBIO granted 58,386 RSUs to EVP/CMO Stephen Pakola and 58,867 RSUs to EVP/CSO Olivier Danos.
RSUs vest over two years with one-fourth vesting every six months, subject to continued service.
Grant aims to retain leadership during a period of CEO transition.

item 5.02

REGENXBIO Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-194111

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.